Senores Pharmaceuticals Limited has plated out a leadership refresh, notifying the market of the re-appointments of two senior executives who are central to the company’s growth agenda. The board has approved the three-year terms for Swapnil Jatinbhai Shah as Managing Director and Chetan Bipinchandra Shah as Whole-Time Director, each effective for three consecutive years starting October 15, 2026 and November 10, 2026, respectively, subject to shareholder approval via postal ballot. The moves underscore the company’s emphasis on continuity at the top as it charts its next phase of expansion across its operations and strategic initiatives.
Swapnil Jatinbhai Shah, the promoter and Managing Director, brings more than 15 years of experience in the pharmaceutical sector. He has been described as leading the company’s overall functioning, with responsibilities spanning product portfolio management, corporate strategy, business development and broader strategic leadership. His academic background includes an MBA from Hofstra University in New York and a bachelor’s degree in chemical engineering from Nirma University. He is also noted for his role as a convenor of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council, reflecting a strong industry footprint.
Chetan Bipinchandra Shah, reappointed as Whole-Time Director, is also the Chief Operating Officer of the company. He brings over three decades of experience, with roughly 25 years in the pharmaceutical sector, having previously served with Torrent Pharmaceuticals and Cadila Pharmaceuticals, and stints with Reliance Retail, Reliance Fresh and Reliance Corporate IT Park. In his capacity as a core member of Senores’ management, he oversees strategy planning, capital expenditure, capacity expansion, policy enforcement, mergers and acquisitions, supply chain (domestic and international), manufacturing processes and automation, risk management and management information systems.
Together, the re-appointments signal Senores Pharmaceuticals’ commitment to experienced, hands-on leadership as it navigates growth opportunities and governance priorities. The company notes that the approvals are to be sought from shareholders via postal ballot, aligning the leadership cadence with its broader governance framework while maintaining momentum in its strategic execution.